Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz

Logo MUG-Forschungsportal

Gewählte Publikation:

Grabenbauer, GG; Rödel, C; Brunner, T; Schulze-Mosgau, S; Strnad, V; Müller, RG; Iro, H; Sauer, R.
Interstitial brachytherapy with Ir-192 low-dose-rate in the treatment of primary and recurrent cancer of the oral cavity and oropharynx. Review of 318 patients treated between 1985 and 1997.
Strahlenther Onkol. 2001; 177(7):338-44 Doi: 10.1007/pl00002416
Web of Science PubMed FullText FullText_MUG

 

Co-Autor*innen der Med Uni Graz
Brunner Thomas Baptist
Altmetrics:

Dimensions Citations:

Plum Analytics:

Scite (citation analytics):

Abstract:
AIM: To evaluate the impact of postoperative interstitial brachytherapy with and without external radiotherapy in the treatment of primary and recurrent squamous cell carcinoma of the oral cavity and oropharynx. PATIENTS AND METHODS: Between 1985 and 1997, a total of 318 patients were treated by interstitial Ir-192 low-dose-rate brachytherapy as part of their primary (n = 236) or recurrent treatment (n = 82). There were 263 male (83%) and 55 (17%) female patients. The distribution of UICC (1997) stages was as follows: I (61 patients, 19%), II (71 patients, 22%), III (58 patients, 18%), IV (128 patients, 40%). The primary tumor site was located in the oral cavity in 201 patients (63%), in the oropharynx in 86 patients (27%), lower lip in 19 patients (6%) and other regions in twelve cases (4%). Treatment concepts did not vary over the time and were dictated by the initial tumor extension: a total of 175 patients (55%) received a combination of surgery, interstitial brachytherapy (23-25 Gy) and external radiotherapy (50-60 Gy), 60 patients (19%) surgery and interstitial brachytherapy (45-55 Gy) alone. Advanced disease not amenable to primary surgery was either treated by radiochemotherapy and interstitial brachytherapy in 39 patients (12%) or a combination of interstitial brachytherapy, external radiotherapy and interstitial hyperthermia in 44 patients (14%). RESULTS: Overall survival rates following primary and recurrent treatment were 50 +/- 4% and 29 +/- 5%, respectively, at 5 years (p < 0.0001). A significant impact on overall survival rate was noted for UICC stage: patients in stage I/II had survival rates of 64 +/- 5% and 57 +/- 10%, respectively, while patients in stage III/IV had survival rates of 39 +/- 5% and 15 +/- 5%, respectively, at 5 years (p < 0.0001). In addition, grading (p = 0.01) and hemoglobin levels (p = 0.05) had a significant influence on overall survival. Local tumor control rates for all patients were 74 +/- 3% and 57 +/- 7% at 5 years following primary and recurrent treatment (p = 0.01), respectively. The 145 patients treated for primary disease by a uniform concept of surgery, interstitial brachytherapy and external radiotherapy achieved excellent local control rates with 92 +/- 4% (stage I/II) and 65 +/- 6% (stage III/IV) at 5 years. Late treatment-related toxicity with soft tissue necrosis and/or osteonecrosis requiring mandibular resection was 7.5%. CONCLUSION: Local tumor excision followed by postoperative interstitial brachytherapy with and without external radiotherapy is associated with excellent locoregional control, a low risk of chronic sequelae and may therefore considered as a new approach avoiding mutilating radical surgery.
Find related publications in this database (using NLM MeSH Indexing)
Brachytherapy - administration & dosage
Carcinoma, Squamous Cell - mortality, pathology, radiotherapy, surgery
Combined Modality Therapy - administration & dosage
Female - administration & dosage
Humans - administration & dosage
Iridium Radioisotopes - therapeutic use
Male - administration & dosage
Middle Aged - administration & dosage
Mouth Neoplasms - pathology, radiotherapy, surgery
Neoplasm Recurrence, Local - diagnostic imaging, mortality, pathology, radiotherapy, surgery
Neoplasm Staging - administration & dosage
Oropharyngeal Neoplasms - mortality, pathology, radiotherapy, surgery
Radiography - administration & dosage
Radiotherapy Dosage - administration & dosage
Radiotherapy, Adjuvant - administration & dosage
Retrospective Studies - administration & dosage
Survival Rate - administration & dosage

Find related publications in this database (Keywords)
head and neck cancer
brachytherapy
radiotherapy
© Med Uni Graz Impressum